22 28 June 2021 ADA R&D investor call Diabetes and Obesity care key take-aw • Novo Nordisk continues aspiring to raise the bar in diabetes ca SUSTAIN FORTE • Insulin innovation continues with development of the novel, on • Two phase 2 trials for cagrisema and semaglutide in combinat exploring opportunities to raise the innovation bar • Semaglutide 2.4 mg shows dynamic weight loss potential, both additional STEP trials
Download PDF file